Biological therapies in rheumatic diseases

被引：57

作者：

Conti, F. ^{[1
]}

Ceccarelli, F. ^{[1
]}

Massaro, L. ^{[1
]}

Cipriano, E. ^{[1
]}

Di Franco, M. ^{[1
]}

Alessandri, C. ^{[1
]}

Spinelli, F. R. ^{[1
]}

Scrivo, R. ^{[1
]}

Valesini, G. ^{[1
]}

机构：

[1] Univ Roma La Sapienza, Dept Internal Med & Med Specialties, I-00185 Rome, Italy

来源：

CLINICA TERAPEUTICA | 2013年 / 164卷 / 05期

关键词：

ankylosing spondylitis; biological drugs; psoriatic arthritis; rheumatoid arthritis; systemic lupus erythematosus; ANTITUMOR-NECROSIS-FACTOR; SYSTEMIC-LUPUS-ERYTHEMATOSUS; FACTOR-ALPHA THERAPY; INTERLEUKIN-1 RECEPTOR ANTAGONIST; ANTIPHOSPHOLIPID ANTIBODY SYNDROME; PLACEBO-CONTROLLED TRIAL; B-CELL DEPLETION; DOUBLE-BLIND; ANKYLOSING-SPONDYLITIS; PSORIATIC-ARTHRITIS;

D O I：

10.7417/CT.2013.1622

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

The development of the biological drugs has revolutionized the therapeutic approach of the chronic inflammatory rheumatic diseases, particularly in patients resistant to standard treatment. These drugs are characterized by an innovative mechanism of action, based on the targeted inhibition of specific molecular or cellular targets directly involved in the pathogenesis of the diseases: pro-inflammatory cytokines (tumor necrosis factor, interleukin-1 and 6), CTLA-4, and molecules involved in the activation, differentiation and maturation of B cells. Their use has indeed allowed for a better prognosis in several rheumatic diseases (such as rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, systemic lupus erythematosus) and to obtain a clinical remission. In the present review we give an overview of the biological drugs currently available for the treatment of the rheumatic diseases, analyzing the different mechanism of action, the therapeutic indications and efficacy data, and adverse events.

引用

页码：E413 / E428

页数：16

共 168 条

[1] Infliximab treatment for ocular and extraocular manifestations of Behcet's disease [J].

Accorinti, Massimo ;

Pirraglia, Maria Pia ;

Paroli, Maria Pia ;

Priori, Roberta ;

Conti, Fabrizio ;

Pivetti-Pezzi, Paola .

JAPANESE JOURNAL OF OPHTHALMOLOGY, 2007, 51 (03) :191-196

[2] Anti-lysobisphosphatidic acid antibodies in patients with antiphospholipid syndrome and systemic lupus erythematosus [J].

Alessandri, C ;

Bombardieri, M ;

Di Prospero, L ;

Conigliaro, P ;

Conti, F ;

Labbadia, G ;

Misasi, R ;

Sorice, M ;

Valesini, G .

CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 2005, 140 (01) :173-180

[3] Role of anti-glial fibrillary acidic protein antibodies in the pathogenesis of neuropsychiatric systemic lupus erythematosus should be clarified: comment on the article by Trysberg et al [J].

Alessandri, C ;

Conti, F ;

Valesini, G .

ARTHRITIS AND RHEUMATISM, 2004, 50 (05) :1698-1699

[4]

Alessandri C, 2012, FASEB J

[5] Autoantibody production in Anti-TNF-α-Treated patients [J].

Alessandri, Cristiano ;

Scrivo, Rossana ;

Spinelli, Francesca Romana ;

Ceccarelli, Fulvia ;

Magrini, Leonardo ;

Priori, Roberta ;

Valesini, Guido .

AUTOIMMUNITY, PT B: NOVEL APPLICATIONS OF BASIC RESEARCH, 2007, 1110 :319-329

[6] Antiphospholipid reactivity against cardiolipin metabolites occurring during endothelial cell apoptosis [J].

Alessandri, Cristiano ;

Sorice, Maurizio ;

Bombardieri, Michele ;

Conigliaro, Paola ;

Longo, Agostina ;

Garofalo, Tina ;

Manganelli, Valeria ;

Conti, Fabrizio ;

Degli Esposti, Mauro ;

Valesini, Guido .

ARTHRITIS RESEARCH & THERAPY, 2006, 8 (06)

[7] Rituximab improves peripheral B cell abnormalities in human systemic lupus erythematosus [J].

Anolik, JH ;

Barnard, J ;

Cappione, A ;

Pugh-Bernard, AE ;

Felgar, RE ;

Looney, RJ ;

Sanz, I .

ARTHRITIS AND RHEUMATISM, 2004, 50 (11) :3580-3590

[8]

[Anonymous], 2000, Am J Respir Crit Care Med, V161, pS221

[9] Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis - Results from the Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT) [J].

Antoni, CE ;

Kavanagh, A ;

Kirkham, B ;

Tutuncu, Z ;

Burmester, GR ;

Schneider, U ;

Furst, DE ;

Molitor, J ;

Keystone, E ;

Gladman, D ;

Manger, B ;

Wassenberg, S ;

Weier, R ;

Wallace, DJ ;

Weisman, MH ;

Kalden, JR ;

Smolen, J .

ARTHRITIS AND RHEUMATISM, 2005, 52 (04) :1227-1236

[10]

Askling J, 2007, ANN RHEUM DIS, V66, P54

← 1 2 3 4 5 6 7 8 9 10 →